Jun 2026 $4 M No. 5 $2 to $10 million 3
Ascendia Pharmaceuticals, Inc.: Raise no. 5, Jun 2026 × Investors in this round 3 investors had bought by the notice of Nov 6, 2026: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $500,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jingjun Huang · Executive Officer, Director Michael Bogda · Executive Officer, Director Robert Bloder · Executive Officer, Director Todd Daviau · Executive Officer James Gale · Director Shoufeng Li · Director Theron Odlaug · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Chelsea Villavicencio Soriano, Authorized Person. Source: SEC Form D and 1 amendment, newest notice filed Nov 6, 2026. Read the notice at the SEC .
equity SEC May 2025 $3 M No. 4 $2 to $10 million 9
Ascendia Pharmaceuticals, Inc.: Raise no. 4, May 2025 × Investors in this round 9 investors had bought by the notice of Jun 4, 2025: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $100,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jingjun Huang · Executive Officer, Director James Gale · Director Robert Bloder · Director Shoufeng Li · Director Theron Odlaug · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jingjun Huang, President & CEO. Source: SEC Form D, newest notice filed Jun 4, 2025. Read the notice at the SEC .
equity SEC Sep 2024 $3 M No. 3 $2 to $10 million 2
Ascendia Pharmaceuticals, Inc.: Raise no. 3, Sep 2024 × Investors in this round 2 investors had bought by the notice of Oct 11, 2024: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $475,121
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Jingjun Huang · Executive Officer, Director James Gale · Director Robert Bloder · Director Shoufeng Li · Director Theron Odlaug · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Oct 11, 2024. Read the notice at the SEC .
equity SEC Jul 2022 $3 M No. 2 $2 to $10 million 2
Ascendia Pharmaceuticals, Inc.: Raise no. 2, Jul 2022 × Investors in this round 2 investors had bought by the notice of Jul 13, 2022: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $474,989
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jingjun Huang · Executive Officer, Director Colin Foster · Director James Gale · Director Robert Bloder · Director Theron Odlaug · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Jul 13, 2022. Read the notice at the SEC .
equity SEC Apr 2021 $5 M No. 1 $2 to $10 million 2
Ascendia Pharmaceuticals, Inc.: Raise no. 1, Apr 2021 × Investors in this round 2 investors had bought by the notice of Apr 20, 2021: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken $949,999
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $300,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Jingjun Huang · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Wombat Capital Markets LLC (CRD 162699) · broker-dealer Wombat Capital Markets LLC (CRD 162699) · New York, New York Sold in NY Remarks in the notice On the amounts: “The offering amount is actually $9,999,999.90, the amount sold to date is $4,999,999.95, and the remaining amount to be sold is $4,999,999.95.”Signed by Dr. Jingjun Huang, President and CEO. Source: SEC Form D, newest notice filed Apr 20, 2021. Read the notice at the SEC .
equity SEC